40 results on '"Schneidawind, Corina"'
Search Results
2. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity
3. Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype
4. B‐cell maturation antigen‐directed bispecific antibodies in plasmablastic lymphoma.
5. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
6. The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia
7. Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia
8. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9
9. PB1803: SMAD1 IS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA WITH MLL REARRANGEMENT
10. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia
11. Supplementary data from E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia
12. Data from E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia
13. Inhibition of effector B cells by ibrutinib in systemic sclerosis
14. Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis
15. Different MLL Breakpoints Influence Leukemia Characteristics of MLL-Rearranged Cells in a Human CRISPR/Cas9-Based Model
16. Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210BCR/ABL1 and p185BCR/ABL1
17. The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia
18. Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation
19. iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis
20. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells
21. Additional file 1 of Inhibition of effector B cells by ibrutinib in systemic sclerosis
22. Only Hematopoietic Stem and Progenitor Cells from Cord Blood Are Susceptible to Malignant Transformation by MLL-AF4 Translocations
23. MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis
24. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner
25. G‐CSF administration prior to donor lymphocyte apheresis promotes anti‐leukaemic effects in allogeneic HCT patients
26. Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation
27. Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity
28. Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9
29. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia
30. MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing
31. SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression
32. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation
33. E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia
34. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLLleukemia model induced by CRISPR/Cas9
35. Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210BCR/ABL1and p185BCR/ABL1
36. Different MLLBreakpoints Influence Leukemia Characteristics of MLL-Rearranged Cells in a Human CRISPR/Cas9-Based Model
37. MycDrives MLLLeukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity
38. Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLLLeukemia Model Induced By CRISPR/Cas9
39. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.
40. MAT2A as Key Regulator and Therapeutic Target in MLL r Leukemogenesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.